What should I do if I become drug-resistant after using Glasgib/Glasgib?

Glasdegib As aHedgehog signaling pathway inhibitor, it has certain efficacy in the treatment of acute myeloid leukemia (AML), especially for elderly or patients who cannot tolerate standard chemotherapy. However, with the prolongation of treatment time, some patients may develop drug resistance, leading to disease progression or reduced efficacy. Faced with the problem of resistance to Glasgib, patients and doctors need to adopt a variety of strategies to delay or overcome resistance.

The main mechanisms of drug resistance includeAdaptive changes in the Hedgehog signaling pathway, changes in drug targets caused by mutations, and tumor cells evading drug effects through other signaling pathways. For example, activation of the Hedgehog pathway in some AML patients may be driven by atypical mutations or activation of bypass signaling. When Glasgib inhibits GLI transcription factors, tumor cells may utilize other pro-proliferative pathways (such as the PI3K/AKT or MAPK pathways) to continue growing.

When a patient develops resistance to Glasgib, the resistance mechanism should first be evaluated through genetic testing to determine subsequent treatment strategies. If resistance is related to mutations in the Hedgehog pathway, doctors may adjust the treatment plan, such as combining it with other targeted drugs, such as the BCL-2 inhibitor Venetoclax or FLT3 inhibitors, to block the alternative growth pathways of cancer cells. In addition, combination chemotherapy is still a feasible option, and studies have shown that the combination of glazegib and low-dose cytarabine (LDAC) can improve the survival of AML patients to a certain extent.

For drug-resistant patients, clinical trials may be a direction worth considering. Multiple studies on the resistance mechanisms of Hedgehog inhibitors and alternative therapies are ongoing globally, such as new generation Hedgehog pathway inhibitors or multi-target inhibitors. These drugs may provide new treatment opportunities for drug-resistant patients.

Reference materials:https://go.drugbank.com/drugs/DB11978